We have located links that may give you full text access.
Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
Annals of Pharmacotherapy 2008 July
OBJECTIVE: To review studies that investigated the use of once-yearly administered intravenous zoledronic acid for the treatment of postmenopausal osteoporosis.
DATA SOURCES: Searches of MEDLINE (1966-February 2008) and EMBASE (1974-February 2008) were conducted using the terms zoledronic acid, once-yearly, and postmenopausal osteoporosis. Literature review was limited to human studies.
STUDY SELECTION AND DATA EXTRACTION: All literature identified from the data sources was evaluated for review inclusion. Studies investigating the use of zoledronic acid in conditions other than postmenopausal osteoporosis, including malignant hypercalcemia, multiple myeloma, and Paget's disease, were excluded. Five randomized controlled studies were included in this review.
DATA SYNTHESIS: Oral bisphosphonates represent one of the most commonly prescribed drug classes for the treatment of postmenopausal osteoporosis. However, due to poor gastrointestinal absorption and poor patient adherence to bisphosphonate therapy, once-yearly intravenous zoledronic acid may be a more attractive option for some patients. Once-yearly zoledronic acid has been shown to decrease bone turnover markers such as serum C-telopeptide by 49-52%, decrease the vertebral fracture rate by approximately 70%, and significantly increase bone mineral density at total hip, femoral neck, and lumbar spine by 6.02%, 5.06%, and 6.71%, respectively. Furthermore, some women may prefer the convenience of once-yearly intravenous zoledronic acid to daily or weekly oral bisphosphonates. In clinical trials that compared once-yearly zoledronic acid infusion with weekly oral alendronate, participants preferred zoledronic acid and found its adverse effect profile to be more favorable.
CONCLUSIONS: Based on available evidence, once-yearly zoledronic acid is an efficacious treatment option for postmenopausal women with osteoporosis. However, lack of head-to-head studies with oral bisphosphonates is a limitation in evaluating its clinical utility. Additional studies investigating zoledronic acid against oral bisphosphonates, specifically looking at rates and types of fractures, are needed to fully determine its place in postmenopausal osteoporosis treatment.
DATA SOURCES: Searches of MEDLINE (1966-February 2008) and EMBASE (1974-February 2008) were conducted using the terms zoledronic acid, once-yearly, and postmenopausal osteoporosis. Literature review was limited to human studies.
STUDY SELECTION AND DATA EXTRACTION: All literature identified from the data sources was evaluated for review inclusion. Studies investigating the use of zoledronic acid in conditions other than postmenopausal osteoporosis, including malignant hypercalcemia, multiple myeloma, and Paget's disease, were excluded. Five randomized controlled studies were included in this review.
DATA SYNTHESIS: Oral bisphosphonates represent one of the most commonly prescribed drug classes for the treatment of postmenopausal osteoporosis. However, due to poor gastrointestinal absorption and poor patient adherence to bisphosphonate therapy, once-yearly intravenous zoledronic acid may be a more attractive option for some patients. Once-yearly zoledronic acid has been shown to decrease bone turnover markers such as serum C-telopeptide by 49-52%, decrease the vertebral fracture rate by approximately 70%, and significantly increase bone mineral density at total hip, femoral neck, and lumbar spine by 6.02%, 5.06%, and 6.71%, respectively. Furthermore, some women may prefer the convenience of once-yearly intravenous zoledronic acid to daily or weekly oral bisphosphonates. In clinical trials that compared once-yearly zoledronic acid infusion with weekly oral alendronate, participants preferred zoledronic acid and found its adverse effect profile to be more favorable.
CONCLUSIONS: Based on available evidence, once-yearly zoledronic acid is an efficacious treatment option for postmenopausal women with osteoporosis. However, lack of head-to-head studies with oral bisphosphonates is a limitation in evaluating its clinical utility. Additional studies investigating zoledronic acid against oral bisphosphonates, specifically looking at rates and types of fractures, are needed to fully determine its place in postmenopausal osteoporosis treatment.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app